These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10634001)

  • 41. [ABO/H blood groups and factor V Leiden].
    Matýsková M; Zavrelová J; Pejchalová A; Meluzinová H; Janků L
    Cas Lek Cesk; 2002 Mar; 141(5):146-51. PubMed ID: 11998221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
    Olave T; Cornudella R; Homs C; Azaceta G; Tirado I; Gutierrez M
    Haematologica; 1998 Apr; 83(4):378-80. PubMed ID: 9592991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High prevalence of factor V Leiden in healthy Jordanian Arabs.
    Awidi A; Shannak M; Bseiso A; Kailani MA; Kailani MA; Omar N; Anshasi B; Sakarneh N
    Thromb Haemost; 1999 Apr; 81(4):582-4. PubMed ID: 10235443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of factor V Leiden in a Canadian blood donor population.
    Lee DH; Henderson PA; Blajchman MA
    CMAJ; 1996 Aug; 155(3):285-9. PubMed ID: 8705907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 46. Prevalence of the FVQ506 (factor V Leiden) mutation in the normal and thrombophilic Algerian population.
    Chafa O; Reghis A; Aubert A; Fischer AM
    Br J Haematol; 1997 Jun; 97(3):688-9. PubMed ID: 9207426
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparison between two functional assays to detect factor V Leiden.
    Gessoni G; Valverde S; Manoni F
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e188-9. PubMed ID: 19228222
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevalence of activated protein C resistance in the Chinese population.
    Ho CH
    Thromb Res; 1997 Dec; 88(5):409-12. PubMed ID: 9556228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Normal prevalence of factor V Leiden gene mutation in patients with severe unstable angina.
    Verheggen PW; Heymans BT; Slagboom PE; Haverkate F; Cats VM
    Thromb Haemost; 1997 Jun; 77(6):1218. PubMed ID: 9241761
    [No Abstract]   [Full Text] [Related]  

  • 50. Children with Legg-Perthes diseases.
    Pokharel RK; Matsuo M; Shiba R; Fujii S
    Clin Orthop Relat Res; 1999 Jun; (363):268-9. PubMed ID: 10379332
    [No Abstract]   [Full Text] [Related]  

  • 51. No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH).
    Lang IM; Klepetko W; Pabinger I
    Thromb Haemost; 1996 Sep; 76(3):476-7. PubMed ID: 8883290
    [No Abstract]   [Full Text] [Related]  

  • 52. Factor V leiden is a risk factor for myocardial infarction in young Turkish men.
    Hobikoglu GF; Akyuz U; Akyuz F; Ozer O; Güney D; Narin A; Unaltuna N
    Acta Cardiol; 2004 Dec; 59(6):594-7. PubMed ID: 15636441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of factor V R506Q mutation in German thrombophilic and normal population.
    Ehrenforth S; Zwinge B; Scharrer I
    Thromb Haemost; 1998 Mar; 79(3):684-5. PubMed ID: 9531062
    [No Abstract]   [Full Text] [Related]  

  • 54. Arterial thromboembolic events in patients with the factor V Leiden mutation.
    Eskandari MK; Bontempo FA; Hassett AC; Faruki H; Makaroun MS
    Am J Surg; 1998 Aug; 176(2):122-5. PubMed ID: 9737615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of factor V Leiden in young adults with retinal vein occlusion.
    Linna T; Ylikorkala A; Kontula K; Puska P; Tervo T
    Thromb Haemost; 1997 Jan; 77(1):214-6. PubMed ID: 9031476
    [No Abstract]   [Full Text] [Related]  

  • 56. Thrombo-embolic disease--prevalence of factor V Leiden in the Western Cape.
    Rubinstein R; Novitzky N
    S Afr Med J; 2001 May; 91(5):406. PubMed ID: 11455804
    [No Abstract]   [Full Text] [Related]  

  • 57. Activated protein C (APC) resistance: does it exist in Basques?
    Bauder F; Ducout L; Guerre C; Freyburger G
    Br J Haematol; 1997 Dec; 99(3):712-3. PubMed ID: 9401095
    [No Abstract]   [Full Text] [Related]  

  • 58. Specificity of 'clotting' methods for factor V Leiden.
    Morse C; Standen G
    Br J Haematol; 1996 Nov; 95(2):432-3. PubMed ID: 8904905
    [No Abstract]   [Full Text] [Related]  

  • 59. Activated protein C resistance assay when applied in the general population.
    Altès A; Souto JC; Mateo J; Borrell M; Fontcuberta J
    Am J Obstet Gynecol; 1997 Feb; 176(2):358-9. PubMed ID: 9065181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activated protein C (APC) resistance in Indian children with thromboembolism.
    Saxena R; Mohanty S; Jain Y
    Br J Haematol; 1999 Apr; 105(1):314-5. PubMed ID: 10366246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.